Exploring the potential benefits of multi-field IMPT for stage I NSCLC SBRT: An in silico dosimetric comparison to IMRT and CyberKnife

Abstract

Purpose: Multi-field intensity-modulated proton therapy (IMPT) is a novel treatment protocol design method proposed to reduce range uncertainty. This study aimed to investigate whether multi-field IMPT has a dose distribution advantage over photon intensity-modulated radiation therapy (IMRT) and CyberKnife in stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC).

Methods: Twenty-nine patients who underwent photon SBRT from February 2021 to September 2022 at Shandong Cancer Hospital were included. Their Computed Tomography (CT) images were used to design CyberKnife and multi-field IMPT plans. For the photon plan (IMRT and CyberKnife), the planning target volume (PTV), which was extended from the internal gross target volume (IGTV), was prescribed at 50 Gy. For the proton plans, the planning beam-specific target volume (PBSTV) based on the IGTV was created to meet the same area as the photon PTV. Multi-field IMPT was simulated by adding additional beam angles to conventional IMPT. Dose distribution assessment factors included D_mean and dose gradient index (GI) for PTV/PBSTV, and D_mean and the hottest 0.1 cm³ dose (D_0.1cc) for organs at risk (OARs).

Results: With each patient receiving 7–11 beams, multi-field IMPT had a better target GI than IMRT. For the lung, heart, spinal cord, chest wall, and ribs doses, the D_mean of the multi-field IMPT was smaller than that of the other two plans for all metrics. CyberKnife was significantly less protective of the OARs than the other two planning modalities, owing to the presence of a high target center dose.

Conclusion: Multi-field IMPT achieves favorable target coverage and OAR protection compared to IMRT and CyberKnife for SBRT of NSCLC.

Keywords

Dosimetric study / Multi-field intensity-modulated proton therapy / Stage I non-small cell lung cancer / Stereotactic body radiotherapy

References

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48.

[2] Lam DC, Liam CK, Andarini S, et al. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023; 18(10): 1303-1322.

[3] Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021; 41(10): 1037-1048.

[4] Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer. 2018; 124(4): 667-678.

[5] Paix A, Noel G, Falcoz PE, Levy P. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiother Oncol. 2018; 128(3): 534-540.

[6] Timmerman RD, Paulus R, Pass HI, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018; 4(9): 1263-1266.

[7] Thompson M, Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res. 2019; 8(1): 48-57.

[8] De Rose F, Franceschini D, Reggiori G, et al. Organs at risk in lung SBRT. Phys Med. 2017; 44: 131-138.

[9] Iwata H, Murakami M, Demizu Y, et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer. 2010; 116(10): 2476-2485.

[10] Welsh J, Gomez D, Palmer MB, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011; 81(5): 1336-1342..

[11] Li Y, Li X, Yang J, et al. Flourish of Proton and Carbon Ion Radiotherapy in China. Front Oncol. 2022; 12: 819905.

[12] Yan S, Ngoma TA, Ngwa W, Bortfeld TR. Global democratisation of proton radiotherapy. Lancet Oncol. 2023; 24(6): e245-e254.

[13] Mohan R, Grosshans D. Proton therapy - Present and future. Adv Drug Deliv Rev. 2017; 109: 26-44.

[14] Doyen J, Falk AT, Floquet V, Hérault J, Hannoun-Lévi JM. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev. 2016; 43: 104-112.

[15] Santos A, Penfold S, Gorayski P, Le H. The Role of Hypofractionation in Proton Therapy. Cancers (Basel). 2022; 14(9): 2271.

[16] Westover KD, Seco J, Adams JA, et al. Proton SBRT for medically inoperable stage I NSCLC. J Thorac Oncol. 2012; 7(6): 1021-1025.

[17] Hoppe BS, Nichols RC, Flampouri S, et al. Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group. Int J Radiat Oncol Biol Phys. 2020; 107(3): 455-461.

[18] Ding X, Li X, Zhang JM, Kabolizadeh P, Stevens C, Yan D. Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy. Int J Radiat Oncol Biol Phys. 2016; 96(5): 1107-1116.

[19] Rah JE, Kim GY, Oh DH, et al. A treatment planning study of proton arc therapy for para-aortic lymph node tumors: dosimetric evaluation of conventional proton therapy, proton arc therapy, and intensity modulated radiotherapy. Radiat Oncol. 2016; 11(1): 140.

[20] Ding X, Zhou J, Li X, et al. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol. 2019; 58(4): 483-490.

[21] Sanchez-Parcerisa D, Kirk M, Fager M, et al. Range optimization for mono- and bi-energetic proton modulated arc therapy with pencil beam scanning. Phys Med Biol. 2016; 61(21): N565-N574.

[22] Liu G, Li X, Qin A, et al. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study. Radiat Oncol. 2020; 15(1): 21.

[23] Toussaint L, Indelicato DJ, Holgersen KS, et al. Towards proton arc therapy: physical and biologically equivalent doses with increasing number of beams in pediatric brain irradiation. Acta Oncol. 2019; 58(10): 1451-1456.

[24] Liu G, Zhao L, Qin A, et al. Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study. Front Oncol. 2021; 11: 664455.

[25] Ding X, Li X, Qin A, et al. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018; 57(3): 435-437.

[26] Wilcox EE, Daskalov GM, Lincoln H, Shumway RC, Kaplan BM, Colasanto JM. Comparison of planned dose distributions calculated by Monte Carlo and Ray-Trace algorithms for the treatment of lung tumors with cyberknife: a preliminary study in 33 patients. Int J Radiat Oncol Biol Phys. 2010; 77(1): 277-284.

[27] Liu R, Buatti JM, Howes TL, Dill J, Modrick JM, Meeks SL. Optimal number of beams for stereotactic body radiotherapy of lung and liver lesions. Int J Radiat Oncol Biol Phys. 2006; 66(3): 906-912.

[28] Mayo CS, Ding L, Addesa A, Kadish S, Fitzgerald TJ, Moser R. Initial experience with volumetric IMRT (RapidArc) for intracranial stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2010; 78(5): 1457-1466.

[29] Reynolds TA, Jensen AR, Bellairs EE, Ozer M. Dose Gradient Index for Stereotactic Radiosurgery/Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020; 106(3): 604-611.

[30] Wagner TH, Bova FJ, Friedman WA, Buatti JM, Bouchet LG, Meeks SL. A simple and reliable index for scoring rival stereotactic radiosurgery plans. Int J Radiat Oncol Biol Phys. 2003; 57(4): 1141-1149.

[31] Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010; 77(2): 357-366.

[32] Kammerer E, Guevelou JL, Chaikh A, et al. Proton therapy for locally advanced breast cancer: A systematic review of the literature. Cancer Treat Rev. 2018; 63: 19-27.

[33] Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol. 2012; 7(1): 165-176.

[34] Argota-Perez R, Elstrøm UV, Jensen K, Korreman SS. Robustness of multifield pseudo-arc proton therapy for sinonasal cancer. Acta Oncol. 2023; 62(5): 508-512.

[35] Qiu B, Men Y, Wang J, Hui Z. Dosimetry, Efficacy, Safety, and Cost-Effectiveness of Proton Therapy for Non-Small Cell Lung Cancer. Cancers (Basel). 2021; 13(18): 4545.

[36] van der Weijst L, Azria D, Berkovic P, et al. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study. Radiother Oncol. 2022; 176: 127-137.

[37] Van der Weijst L, Aguado-Barrera ME, Azria D, et al. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer. 2022; 166: 228-241.

[38] Harris WB, Zou W, Cheng C, et al. Higher Dose Volumes May Be Better for Evaluating Radiation Pneumonitis in Lung Proton Therapy Patients Compared With Traditional Photon-Based Dose Constraints. Adv Radiat Oncol. 2020; 5(5): 943-950.

[39] Ran J, Wang J, Bi N, et al. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. Radiat Oncol. 2017; 12(1): 195.

[40] Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest. 2012; 141(4): 858-866.

[41] Wink KCJ, Roelofs E, Simone CB, et al. Photons, protons or carbon ions for stage I non-small cell lung cancer - Results of the multicentric ROCOCO in silico study. Radiother Oncol. 2018; 128(1): 139-146.

[42] Siaravas KC, Katsouras CS, Sioka C. Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int J Mol Sci. 2023; 24(7): 6272.

[43] Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart. 2016; 102(4): 269-276.

[44] de Jong BA, Battinelli C, Free J, et al. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. Med Phys. 2023; 50(3): 1305-1317.

[45] Paganetti H, Beltran C, Both S, et al. Roadmap: proton therapy physics and biology. Phys Med Biol. 2021; 66(5).

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.